Search clinical trials for: Vadimezan

Total 14 results

Novartis Pharmaceuticals

Terminated

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer (ATTRACT-2)

Non-Small Cell Lung Cancer

United States, Germany, Belgium, Italy, France, Canada, Hungary, Poland, Switzerland, Spain
Novartis Pharmaceuticals

Terminated

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer (ATRACT-1)

Non-Small Cell Lung Cancer

United States, Greece, Hong Kong, Taiwan, Argentina, Germany, United Kingdom, Singapore, Italy, Spain, France, Korea, Republic of, Netherlands, Brazil, Canada and more
Novartis Pharmaceuticals

Terminated

A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

Metastatic Cancer

United States
Novartis Pharmaceuticals

Completed

An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

Japan
Novartis Pharmaceuticals

Completed

Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors

Advanced or Recurrent Solid Tumors

Japan
Novartis Pharmaceuticals

Terminated

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Metastatic Cancer With Impaired Renal Function | Metastatic Cancer With Normal Renal Function

Belgium
Novartis Pharmaceuticals

Terminated

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Histologically-proven and Radiologically-confirmed Solid Tumors

Italy, New Zealand
Novartis Pharmaceuticals

Terminated

A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

Advanced Solid Tumors

New Zealand
University of Glasgow

Completed

Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
University of California, San Francisco

Withdrawn

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

Tumors

United States
Novartis Pharmaceuticals

Terminated

A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies

Solid Tumor Malignancies

United States
Novartis Pharmaceuticals

Terminated

Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor

Solid Tumors

United States
Cancer Research UK

Completed

Study of DMXAA (Now Known as ASA404) in Solid Tumors (DMXAA)

Solid Tumors
Antisoma Research

Completed

Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

X